Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals

A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals

Thumbnail Image
Download
Name

12967_2020_Article_2476.pdf

Size

906.64 KB

Format

Adobe PDF

Checksum (MD5)

be7de77511e9a8b5d4ed1a5575865aed

Download all files submitted through automated deposit
art_2058423289194815101.zip (733.4 KB)
Author(s)
Chitalia, Vipul C.
•
Munawar, Ali H
Date Issued
October 2020
Journal
Journal of Translational Medicine
Publisher
BioMed Central
Citation
Chitalia, Vipul C. and Ali H. Munawar. "A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals." Journal of Translational Medicine 18, 1 (October 2020): 390 © 2020 Springer Nature
Version
Final published version
Abstract
While the COVID-19 pandemic has spurred intense research and collaborative discovery worldwide, the development of a safe, effective, and targeted antiviral from the ground up is time intensive. Therefore, most antiviral discovery efforts are focused on the re-purposing of clinical stage or approved drugs. While emerging data on drugs undergoing COVID-19 repurpose are intriguing, there is an undeniable need to develop broad-spectrum antivirals to prevent future viral pandemics of unknown origin. The ideal drug to curtail rapid viral spread would be a broad-acting agent with activity against a wide range of viruses. Such a drug would work by modulating host-proteins that are often shared by multiple virus families thereby enabling preemptive drug development and therefore rapid deployment at the onset of an outbreak. Targeting host-pathways and cellular proteins that are hijacked by viruses can potentially offer broad-spectrum targets for the development of future antiviral drugs. Such host-directed antivirals are also likely to offer a higher barrier to the development and selection of drug resistant mutations. Given that most approved antivirals do not target host-proteins, we reinforce the need for the development of such antivirals that can be used in pre- and post-exposure populations.
MIT Department
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Creative Commons Attribution
https://creativecommons.org/licenses/by/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/128105
DOI of Published Version
https://doi.org/10.1186/s12967-020-02476-9
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.